Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements
CONCLUSIONS: AdCC-BGs constitute a convergent phenotype, whereby activation of MYB or MYBL1 can be driven by the MYB::NFIB fusion gene or MYBL1 rearrangements. Our observations further support the notion that AdCCs, irrespective of organ site, constitute a genotypic-phenotypic correlation. Assessment of MYB or MYBL1 rearrangements may be used as an ancillary marker for the diagnosis of AdCC-BGs.PMID:38368814 | DOI:10.1016/j.ygyno.2024.02.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Jacqueline Feinberg Arnaud Da Cruz Paula Edaise M da Silva Fresia Pareja Juber Patel Yingjie Zhu Pier Selenica Mario M Leitao Nadeem R Abu-Rustum Jorge S Reis-Filho Amy Joehlin-Price Britta Weigelt Source Type: research

Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment
CONCLUSION: A majority of included patients had a history of trauma exposure prior to VBT. In a subset of patients, VBT re-induced trauma and was considered to be an independent traumatic event. This study highlights the importance of practicing trauma informed care, particularly in this patient population.PMID:38368815 | DOI:10.1016/j.ygyno.2024.02.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Anjali L Saripalli Dylan H Ross Elizabeth Murphy Kay éromi Gomez Sarah Thilges Matthew M Harkenrider Source Type: research

EGFL6 promotes endometrial cancer cell migration and proliferation
CONCLUSIONS: EGFL6 is a marker of poor prognosis endometrial cancers, driving cancer cell proliferation and growth. As such EGFL6 represents a potential therapeutic target in endometrial cancer.PMID:38368816 | DOI:10.1016/j.ygyno.2024.02.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Alison A Garrett Shoumei Bai Sandra Cascio Navneet Gupta Dongli Yang Ronald J Buckanovich Source Type: research

Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy
CONCLUSION: In this population, inadequate follow up for abnormal cervical cytology during pregnancy is prominent, especially among those with younger maternal age, African American (AA) race, cervical cytology completed at later gestational ages of pregnancy, and low-grade initial cytology. Higher no-show rate among AA patients supports well-documented health disparities and need for further investigation and protocols to identify those at risk for loss to follow up.PMID:38368812 | DOI:10.1016/j.ygyno.2024.01.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Kelsey A Roof Hannah K Wichmann Laura J Carlton Minh L Nguyen George G Birdsong Danielle M Blemur Lisa C Flowers Source Type: research

The impact of body mass index on robotic surgery outcomes in endometrial cancer
CONCLUSION: BMI does not affect the peri-operative outcome of patients undergoing robotic staging procedures for endometrial cancer.PMID:38368813 | DOI:10.1016/j.ygyno.2024.01.051 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Eva Kadoch Yoav Brezinov Gabriel Levin Florentin Racovitan Susie Lau Shannon Salvador Walter H Gotlieb Source Type: research

Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements
CONCLUSIONS: AdCC-BGs constitute a convergent phenotype, whereby activation of MYB or MYBL1 can be driven by the MYB::NFIB fusion gene or MYBL1 rearrangements. Our observations further support the notion that AdCCs, irrespective of organ site, constitute a genotypic-phenotypic correlation. Assessment of MYB or MYBL1 rearrangements may be used as an ancillary marker for the diagnosis of AdCC-BGs.PMID:38368814 | DOI:10.1016/j.ygyno.2024.02.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Jacqueline Feinberg Arnaud Da Cruz Paula Edaise M da Silva Fresia Pareja Juber Patel Yingjie Zhu Pier Selenica Mario M Leitao Nadeem R Abu-Rustum Jorge S Reis-Filho Amy Joehlin-Price Britta Weigelt Source Type: research

Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment
CONCLUSION: A majority of included patients had a history of trauma exposure prior to VBT. In a subset of patients, VBT re-induced trauma and was considered to be an independent traumatic event. This study highlights the importance of practicing trauma informed care, particularly in this patient population.PMID:38368815 | DOI:10.1016/j.ygyno.2024.02.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Anjali L Saripalli Dylan H Ross Elizabeth Murphy Kay éromi Gomez Sarah Thilges Matthew M Harkenrider Source Type: research

EGFL6 promotes endometrial cancer cell migration and proliferation
CONCLUSIONS: EGFL6 is a marker of poor prognosis endometrial cancers, driving cancer cell proliferation and growth. As such EGFL6 represents a potential therapeutic target in endometrial cancer.PMID:38368816 | DOI:10.1016/j.ygyno.2024.02.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Alison A Garrett Shoumei Bai Sandra Cascio Navneet Gupta Dongli Yang Ronald J Buckanovich Source Type: research

Factors associated with loss to follow up after abnormal cervical cancer screening in pregnancy
CONCLUSION: In this population, inadequate follow up for abnormal cervical cytology during pregnancy is prominent, especially among those with younger maternal age, African American (AA) race, cervical cytology completed at later gestational ages of pregnancy, and low-grade initial cytology. Higher no-show rate among AA patients supports well-documented health disparities and need for further investigation and protocols to identify those at risk for loss to follow up.PMID:38368812 | DOI:10.1016/j.ygyno.2024.01.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Kelsey A Roof Hannah K Wichmann Laura J Carlton Minh L Nguyen George G Birdsong Danielle M Blemur Lisa C Flowers Source Type: research

The impact of body mass index on robotic surgery outcomes in endometrial cancer
CONCLUSION: BMI does not affect the peri-operative outcome of patients undergoing robotic staging procedures for endometrial cancer.PMID:38368813 | DOI:10.1016/j.ygyno.2024.01.051 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Eva Kadoch Yoav Brezinov Gabriel Levin Florentin Racovitan Susie Lau Shannon Salvador Walter H Gotlieb Source Type: research

Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements
CONCLUSIONS: AdCC-BGs constitute a convergent phenotype, whereby activation of MYB or MYBL1 can be driven by the MYB::NFIB fusion gene or MYBL1 rearrangements. Our observations further support the notion that AdCCs, irrespective of organ site, constitute a genotypic-phenotypic correlation. Assessment of MYB or MYBL1 rearrangements may be used as an ancillary marker for the diagnosis of AdCC-BGs.PMID:38368814 | DOI:10.1016/j.ygyno.2024.02.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Jacqueline Feinberg Arnaud Da Cruz Paula Edaise M da Silva Fresia Pareja Juber Patel Yingjie Zhu Pier Selenica Mario M Leitao Nadeem R Abu-Rustum Jorge S Reis-Filho Amy Joehlin-Price Britta Weigelt Source Type: research

Prevalence of trauma history and symptoms in patients who have received vaginal brachytherapy as part of their endometrial cancer treatment
CONCLUSION: A majority of included patients had a history of trauma exposure prior to VBT. In a subset of patients, VBT re-induced trauma and was considered to be an independent traumatic event. This study highlights the importance of practicing trauma informed care, particularly in this patient population.PMID:38368815 | DOI:10.1016/j.ygyno.2024.02.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Anjali L Saripalli Dylan H Ross Elizabeth Murphy Kay éromi Gomez Sarah Thilges Matthew M Harkenrider Source Type: research

EGFL6 promotes endometrial cancer cell migration and proliferation
CONCLUSIONS: EGFL6 is a marker of poor prognosis endometrial cancers, driving cancer cell proliferation and growth. As such EGFL6 represents a potential therapeutic target in endometrial cancer.PMID:38368816 | DOI:10.1016/j.ygyno.2024.02.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 18, 2024 Category: Cancer & Oncology Authors: Alison A Garrett Shoumei Bai Sandra Cascio Navneet Gupta Dongli Yang Ronald J Buckanovich Source Type: research

The impact of Black founding fathers on the specialty of gynecologic oncology
CONCLUSION: These three men represent the Black Founding Fathers of gynecologic oncology. Their perseverance in the face of adversity and commitment to excellence have left an indelible impact on the institutions that they developed, the individuals that they trained, and the patients that they served.PMID:38367302 | DOI:10.1016/j.ygyno.2024.02.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 17, 2024 Category: Cancer & Oncology Authors: Michael L Hicks Roland P Matthews Camille A Clare Yolanda R Lawson Dineo Khabele Maya M Hicks Cyril O Spann Groesbeck P Parham Source Type: research

Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center
CONCLUSIONS: Our findings along with previously published data suggest that apixaban should be considered the standard of care for VTE prophylaxis in patients undergoing open surgery for gynecologic malignancies.PMID:38368180 | DOI:10.1016/j.ygyno.2024.01.039 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 17, 2024 Category: Cancer & Oncology Authors: Anne Knisely Maria D Iniesta Samantha Batman Larissa A Meyer Pamela T Soliman Katherine E Cain Claire Marten Gary Chisholm Kathleen M Schmeler Jolyn S Taylor Nicole D Fleming Source Type: research